Navigation Links
Experimental Chemo Combo for Colon Cancer Disappoints
Date:4/3/2012

TUESDAY, April 3 (HealthDay News) -- Adding the drug cetuximab (brand name Erbitux) to standard chemotherapy after surgery for stage 3 colon cancer did not improve disease-free survival in patients, a new study concludes.

Patients with stage 3 colon cancer who undergo surgery have a 50 percent chance of cure, and clinical trials have found that chemotherapy with the drugs leucovorin, fluorouracil and oxaliplatin (a regimen known as FOLFOX) after surgery can cut the odds for colon cancer's return.

Staging refers to the severity of cancer. A stage 3 cancer has spread nearby, while a stage 4 cancer has spread to another organ.

This study of almost 2,700 patients investigated the addition of cetuximab to the FOLFOX regimen and found that it provided no extra benefit.

Three-year disease-free survival for patients who received the FOLFOX regimen alone ranged from 67 percent to 75 percent, compared with 65 percent to 72 percent for those who also received cetuximab, the study found.

The study appears in the April 4 issue of the Journal of the American Medical Association.

The time to cancer recurrence and overall survival was similar in both groups, said Dr. Steven Alberts, of the Mayo Clinic in Rochester, Minn., and colleagues in a journal news release.

It's not clear why the addition of cetuximab to the FOLFOX regimen did not benefit patients, the researchers noted.

Dr. Richard Whelan, chief of colorectal surgery at St. Luke's-Roosevelt Hospital in New York City, explained that the drug had shown promise with other patients.

"Cetuximab was added to the FOLFOX regimen based on promising results noted when this agent was given to stage 4 colon cancer patients either alone or with other chemotherapy agents," said Whelan, who was not involved in the new study. "Unfortunately, what works in one setting may not prove equally effective in a different population of patients. Researchers will continue to search for new drug combinations that are more effective than the present regimens."

Cetuximab still has a role in the treatment of certain patients with stage 4 cancer, Whelan said.

And another expert said that, even though the drug failed to help these patients, important lessons have still been learned.

"Although this is a negative study, there is a benefit to patient care," said Dr. David Bernstein, chief, division of gastroenterology at North Shore University Hospital in Manhasset, N.Y. "The increased toxicity [side effects] seen with the addition of cetuximab did not translate into increased survival, and therefore this drug can be removed from the treatment cocktail without sacrificing outcome, and by its removal, lessen patient adverse events on therapy."

More information

The U.S. National Cancer Institute has more about colon cancer treatment.

-- Robert Preidt

SOURCES: Richard Whelan, M.D., chief of colorectal surgery, St. Luke's-Roosevelt Hospital, New York City; David Bernstein, M.D., chief, division of gastroenterology, North Shore University Hospital, Manhasset, N.Y.; Journal of the American Medical Association, news release, April 3, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Pill May Ease Multiple Sclerosis Disability
2. Experimental Drug Shows Promise Against Cushings Disease
3. Experimental Drug Offers Hope for Rare Bone Disease: Study
4. Experimental Drug Shows Promise Against Type 2 Diabetes
5. First-in-human drug for malignant glioma available in experimental trial
6. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
7. Experimental Drugs Do Battle Against Advanced Prostate Cancer
8. Experimental Blood Thinner Given Before Surgery Shows Benefit
9. Wolfson Foundation awards £20 million to UCL for experimental neurology center
10. Novel experimental agent is highly active in CLL patients, interim study shows
11. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Chemo Combo for Colon Cancer Disappoints
(Date:5/26/2016)... ... 26, 2016 , ... Intalere, the healthcare industry leader in ... inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May 17-20, ... America’s healthcare providers. , The conference was highlighted by the announcement of the ...
(Date:5/26/2016)... ... 26, 2016 , ... The Woodlands at John Knox Village , Florida’s ... care for living and healing, celebrated its grand opening, today. The Woodlands at John ... provided by Empowered Staff. , “This is an incredibly fulfilling time for John Knox ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... development solutions for drugs, biologics, consumer health and global clinical supply services, today ... Korea to support the company’s continued investment and strategic growth plans in the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
(Date:5/26/2016)... ... 26, 2016 , ... North Cypress Medical Center hosted its 9th ... Cypress. With the help of community partners, the event organizers raised $45,000 for the ... wounded service members and their families through health, wellness, and therapeutic support. , ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/26/2016)... WELLESLEY, Massachusetts , May 26, 2016 ... sequencing (NGS) has matured into an essential life science ... research and development applications. BCC Research reveals in its ... of a second growth phase, one powered by a ... applied fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology: